Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Mayo Clinic, BioSig starting coronavirus drug trial

By Sean Whooley | April 16, 2020

BioSig Technologies (NSDQ:BSGM) announced today that it is beginning a Phase II clinical trial at Mayo Clinic for Vicromax as a treatment for COVID-19.

ViralClear Pharmaceuticals, a subsidiary of BioSig, updated its clinical development program for the Vicromax treatment which is slated to be used in a trial under Dr. Andrew Badley, the professor and chair of Mayo Clinic’s department of molecular medicine and enterprise chair of its COVID-19 task force.

Vicromax is an antiviral candidate also known as merimepodib (MMPD), designed to target RNA-dependent polymerases. Safety data from over 300 patients treated for hepatitis C revealed satisfactory results from the treatment, according to a news release. A recent manuscript titled “The IMPDH inhibitor merimepodib suppresses SARS-COV-2 replications” demonstrated decreased viral production at a rate of more than 98% with MMPD.

The Phase II clinical trial is set to be a randomized, placebo-controlled study. ViralClear and May Clinic anticipate data from the trial within three months.

“Evaluating efficacy of Vicromax ™ (MMPD) in patients is a top priority, and we are pleased that Mayo Clinic agreed to work with us on this critically important mission,” BioSig chairman & CEO Kenneth Londoner said in the release.

“Over the past few weeks, we worked very closely with Dr. Badley to understand the optimal mechanism of a trial which would not be disruptive to those on the frontline of the pandemic and would allow the industry to generate clinically relevant data,” ViralClear executive chairman Dr. Jerome Zeldis added. “We are optimistic that Vicromax as a host-directed therapy will become a significant tool within the multi-faceted and rapidly-evolving COVID-19 standard of care.”

The Phase II trial will be the latest in pursuit of coronavirus treatments, after Bausch Health (NYSE:BHC), Eli Lilly (NYSE:LLY) and Care Access Research, all announced clinical testing of coronavirus therapies recently.


Filed Under: clinical trials, Drug Discovery, Drug Discovery and Development, Infectious Disease
Tagged With: BioSig Technologies, coronavirus, covid-19, Mayo Clinic, ViralClear Pharmaceuticals
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

CNS
The CNS drug development drum beat is getting louder
DeepMind
7 ways DeepMind’s AlphaFold is being used in life sciences
Biomarker
Bioanalytical method development and validation using Quanterix’s Simoa platform 
FDA logo
FDA could approve MDMA and psilocybin in 2 years

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50